Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Changing frequency of equivocal HER-2/neu scores and factors predictive of negative HER 2/neu fluorescent in situ hybridisation in invasive carcinomas of the breast.

Journal of clinical pathology - 1 Mar 2014

Boulos Fouad, Farra Chantal G, Saad Aldin Ehab M, Masaad Cleo, Hassoun Yasmin, Fedda Faysal, Doumiati Hassan, Tawil Ayman N, Nasser Zeina, Nahleh Zeina, Tfayli Arafat

Abstract excerpt

BACKGROUND: Analysis of human epidermal growth factor receptor 2 (HER-2) status has become standard of care in breast cancer patients due to its important prognostic and therapeutic implications. Immunohistochemistry (IHC) is the most commonly used primary method for detection of HER-2 overexpression. Controversy exists on the interpretation of samples that are equivocal for HER 2 status (IHC 2+). Recent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma
Share to In Situ Hybridization, Fluorescence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lebanon

Share to Neoplasm Grading

Share to Neoplasm Invasiveness

Share to Predictive Value of Tests

Share to Receptor, ErbB-2

Share to Receptors, Progesterone

Source

Identifiers

PMID: 24108431
DOI: 10.1136/jclinpath-2013-201546

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Changing frequency of equivocal HER-2/neu scores and factors predictive of negative HER 2/neu fluorescent in situ hybridisation in invasive carcinomas of the breast.PMID 24108431Read ↗

HER2 gene amplification in patients with breast cancer with equivocal IHC resultsSemantic proximity Read ↗

Exploring the Heterogeneity of HER2 gene status and Expression in Non-Positive Breast Cancer Patients: Insights from Immunohistochemistry and Fluorescence In Situ HybridizationSemantic proximity Read ↗

Discordance between Equivocal HER2 Immunohistochemistry and Fluorescence in Situ Hybridization Analysis among the Breast Carcinoma Patients in Bangladesh: A Series of 75 CasesSemantic proximity Read ↗

Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancersSemantic proximity Read ↗

Assessing the New American Society of Clinical Oncology/College of American Pathologists Guidelines for HER2 Testing by Fluorescence In Situ Hybridization: Experience of an Academic Consultation PracticeSemantic proximity Read ↗

Gene Status in HER2 Equivocal Breast Carcinomas: Impact of Distinct Recommendations and Contribution of a Polymerase Chain Reaction-Based MethodSemantic proximity Read ↗

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic ConsiderationsSemantic proximity Read ↗

Unusual Patterns of HER2 Expression in Breast Cancer: Insights and PerspectivesSemantic proximity Read ↗

Her-2/neu overexpression due to polysomy 17 in breast cancer: molecular testing to guide therapeutic options.Semantic proximity Read ↗

Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond.Semantic proximity Read ↗

Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization1 1This manuscript consists of original material not previously accepted for publication by another journal. The manuscript does not include use of any investigational or “off-label” products. The authors do not have a financial or other relationship with any of the commercial enterprises whose products or services may be discussed in this original a…Semantic proximity Read ↗

Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.